We are delighted to announce that 𝑩𝒊𝒐𝒗𝒆𝒏𝒕𝒖𝒓𝒆 and 𝑨𝒎𝒎𝒂𝒏 𝑷𝒉𝒂𝒓𝒎𝒂𝒄𝒆𝒖𝒕𝒊𝒄𝒂𝒍 𝑰𝒏𝒅𝒖𝒔𝒕𝒓𝒊𝒆𝒔 signed an exclusive licensing agreement for the commercialization of 𝐀𝐟𝐥𝐢𝐛𝐞𝐫𝐜𝐞𝐩𝐭 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 in the Levant region.
#GlobalOneHealthcare #Bioventure #AmmanPharmaceuticalIndustries #AmmanPharma
Amman Pharmaceutical Industries (API) was established in 1989 as one of the first pharmaceutical companies in the MENA region to pioneer the production of niche branded generics in the therapeutic areas of Ophthalmology, ENT (Ear, Nose & Throat ) , respiratory, and Dermatology. After many years of success.
